Health Care & Life Sciences » Pharmaceuticals | TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
2,276.00
35,000.00
52,156.00
44,413.00
34,466.00
39,104
Other Current Assets
99.00
728.00
1,150.00
1,235.00
1,591.00
1,499
Total Current Assets
2,375.00
35,728.00
53,306.00
45,648.00
36,057.00
40,603
Net Property, Plant & Equipment
20.00
97.00
173.00
82.00
73.00
45
Other Assets
24.00
2,346.00
43.00
-
-
-
Total Assets
2,419.00
38,171.00
53,522.00
45,730.00
36,130.00
40,648
ST Debt & Current Portion LT Debt
774.00
4,676.00
1,378.00
1,183.00
2,837.00
Accounts Payable
-
3,974.00
8,281.00
6,213.00
6,800.00
Other Current Liabilities
1,273.00
4,603.00
4,516.00
2,847.00
2,161.00
Total Current Liabilities
2,047.00
13,253.00
14,175.00
10,243.00
11,798.00
Long-Term Debt
1,764.00
4,258.00
7,464.00
7,130.00
4,603.00
Other Liabilities
23.00
2,954.00
905.00
21.00
2,742.00
Total Liabilities
3,834.00
20,465.00
22,544.00
17,394.00
19,143.00
Common Equity (Total)
25,344.00
32,174.00
30,978.00
28,336.00
16,987.00
Total Shareholders' Equity
25,344.00
32,174.00
30,978.00
28,336.00
16,987.00
Total Equity
25,344.00
32,174.00
30,978.00
28,336.00
16,987.00
Liabilities & Shareholders' Equity
2,419.00
38,171.00
53,522.00
45,730.00
36,130.00
Non-Equity Reserves
23,929.00
49,880.00
-
-
-

About TRACON Pharmaceuticals

View Profile
Address
4350 La Jolla Village Drive
San Diego California 92122
United States
Employees -
Website http://www.traconpharma.com
Updated 07/08/2019
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.